Trial · NCT02966834
Adverse events1,080
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,080
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Placebo - Main Study Period | 3 | 36 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 20 mg QD - Main Study Period | 3 | 16 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg QD - Main Study Period | 4 | 23 | 6 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 180 mg QD - Main Study Period | 8 | 27 | 9 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 40 mg BID - Main Study Period | 2 | 23 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg BID - Main Study Period | 4 | 22 | 5 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo - Final Study Period | 0 | 35 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 20 mg QD - Final Study Period | 1 | 16 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg QD - Final Study Period | 0 | 19 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 180 mg QD - Final Study Period | 0 | 19 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 40 mg BID - Final Study Period | 0 | 21 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg BID - Final Study Period | 0 | 17 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo - Follow-up | 0 | 35 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 20 mg QD - Follow-up | 0 | 16 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg QD - Follow-up | 0 | 23 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 180 mg QD - Follow-up | 0 | 27 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 40 mg BID - Follow-up | 0 | 22 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | GSK2330672 90 mg BID - Follow-up | 0 | 22 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Placebo - Main Study Period | 0 | 36 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | GSK2330672 20 mg QD - Main Study Period | 1 | 16 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02966834/events